Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Predictive markers in breast cancer--the present.

S J L Payne1, R L Bowen, J L Jones

  • 1Tumour Biology Laboratory, Institute of Cancer, John Vane Science Centre, Queen Mary's School of Medicine and Dentistry, London, UK.

Histopathology
|January 4, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Insurance, Assurance and Insolence.

Texas medical journal (Austin, Tex.)·2023
Same author

Cross-tissue immune cell analysis reveals tissue-specific features in humans.

Science (New York, N.Y.)·2022
Same author

A method to isolate and cryopreserve cerebrospinal fluid mononuclear cells from external ventricular drains to investigate immunological processes in acute brain injuries.

Journal of immunological methods·2021
Same author

Risk factors for <i>Toxoplasma gondii</i> seropositivity in the Old Order Amish.

Epidemiology and infection·2020
Same author

Identification of a Sacral, Visceral Sensory Transcriptome in Embryonic and Adult Mice.

eNeuro·2020
Same author

The immunological response to traumatic brain injury.

Journal of neuroimmunology·2019
Same journal

TROP2 immunoreactivity in pulmonary large cell neuroendocrine carcinoma.

Histopathology·2026
Same journal

Malignant adenomyoepithelioma of the breast: seven cases illustrating morphological diversity and diagnostic challenges.

Histopathology·2026
Same journal

A CRX-positive RB1-deficient bone tumour with a retinoblastoma-like DNA methylation profile.

Histopathology·2026
Same journal

Perivascular epithelioid cell tumours of the genitourinary tract: clinicopathological features and molecular landscape.

Histopathology·2026
Same journal

Navigating diagnostic challenges in low-grade spindle cell lesions of the breast: a retrospective review.

Histopathology·2026
Same journal

Neoplastic transformation of sporadic gastric hyperplastic polyps: a systematic review and meta-analysis of risk factors and clinicopathological features.

Histopathology·2026
See all related articles

This review covers established breast cancer markers: oestrogen receptor (ER), progesterone receptor (PR), and HER-2. It discusses their roles in prognosis, treatment response, and current assessment standards, highlighting limitations and future directions.

Area of Science:

  • Oncology
  • Biomarker Research
  • Clinical Pathology

Background:

  • Breast cancer is a complex disease requiring accurate prognostic and predictive markers.
  • Established markers like oestrogen receptor (ER), progesterone receptor (PR), and HER-2 are crucial for patient management.
  • Current limitations exist in marker predictive power and assessment standardization.

Purpose of the Study:

  • To review the established roles of ER, PR, and HER-2 in breast cancer patient management.
  • To outline current standards for assessing these key biological markers.
  • To highlight existing controversies and potential refinements in marker assessment and utilization.

Main Methods:

  • Literature review of established breast cancer prognostic and predictive markers.

Related Experiment Videos

  • Analysis of current clinical guidelines and assessment standards for ER, PR, and HER-2.
  • Discussion of controversies and future directions in biomarker research for breast cancer.

    • Main Results:

    • Oestrogen receptor (ER) is a primary predictive marker for prognosis and hormone therapy response.
    • Progesterone receptor (PR) is widely used, though its predictive value is less defined than ER.
    • HER-2 status is a routine prognostic and predictive factor in breast cancer management.

    Conclusions:

    • Robust and standardized assays for ER, PR, and HER-2 are essential for reliable patient management.
    • Understanding the limitations of current markers is key to refining breast cancer prognosis and treatment selection.
    • Further research into additional biological markers may enhance predictive accuracy.